Trials / Conditions / Refractory Anemia With Excess Blasts in Transformation

Refractory Anemia With Excess Blasts in Transformation

22 registered clinical trials studyying Refractory Anemia With Excess Blasts in Transformation.

Status	Trial	Sponsor	Phase
Completed	Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome NCT02553941	Brian Jonas	Phase 1
Completed	DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or A NCT01834248	Roswell Park Cancer Institute	Phase 1
Completed	Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematolo NCT01175785	Nohla Therapeutics, Inc.	Phase 2
Completed	Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia NCT01146210	Children's Oncology Group	—
Completed	A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Bloo NCT00343798	Fred Hutchinson Cancer Center	Phase 1
Completed	Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia NCT00357565	Masonic Cancer Center, University of Minnesota	Phase 2
Completed	SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic NCT00098826	National Cancer Institute (NCI)	Phase 1
Completed	Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lym NCT00098423	National Cancer Institute (NCI)	Phase 1
Completed	XK469R in Treating Patients With Refractory Hematologic Cancer NCT00095797	National Cancer Institute (NCI)	Phase 1
Completed	Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or NCT00096122	National Cancer Institute (NCI)	Phase 1 / Phase 2
Completed	Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic S NCT00087204	National Cancer Institute (NCI)	Phase 1
Completed	CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, NCT00084916	National Cancer Institute (NCI)	Phase 2
Terminated	Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Trans NCT00119366	Fred Hutchinson Cancer Center	Phase 2
Completed	Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leuke NCT00052520	Fred Hutchinson Cancer Center	Phase 1 / Phase 2
Completed	Tipifarnib in Treating Patients With Myelodysplastic Syndromes NCT00005845	National Cancer Institute (NCI)	Phase 1
Completed	Thalidomide in Treating Patients With Myelodysplastic Syndrome NCT00015990	National Cancer Institute (NCI)	Phase 2
Completed	BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia NCT00006213	National Cancer Institute (NCI)	Phase 1
Completed	Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initi NCT00005942	National Cancer Institute (NCI)	Phase 1 / Phase 2
Completed	PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, NCT00005064	National Cancer Institute (NCI)	Phase 1
Completed	Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemi NCT00004918	National Cancer Institute (NCI)	Phase 1 / Phase 2
Completed	Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed NCT00008177	Fred Hutchinson Cancer Center	Phase 1
Completed	Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogeno NCT00002798	National Cancer Institute (NCI)	Phase 3